A European Union-funded project called Biogo-For-Production, the joint effort of 15 partners from eight countries, developed innovative nanocatalysts that are used to transform sustainable sources into biofuel. The nanoscale catalysts are prepared using a novel technology that offers reduced dependence on precious metals and rare earth materials.
Johnson & Johnson subsidiary Cerenovus has informed health care providers that it stopped production of its implantable Codman pumps, which are designed to deliver high chemotherapy doses to the liver to treat metastatic cancer at the site, because of problems with the supply of titanium rods and other raw materials. Mindy Tinsley, a spokeswoman for Cerenovus, said the company was continuing to explore alternatives, although she said demand for the pumps was "very low" with US sales of approximately 300 pumps each year.
Abbott said it will no longer sell its Xience Alpine drug-eluting stent in India beginning today after fulfilling all requirements needed to pull its product from the market. The company said the ceiling price set by the National Pharmaceutical Pricing Authority makes the continued supply of its stent unsustainable, although it will consider reselling the stent in the country "if it becomes commercially viable."
A seed investment round led by Atlantic Bridge University Fund pulled in $4.2 million for ProVerum Medical, an Irish startup that is developing a device for the treatment of benign prostatic hyperplasia. The proceeds will be used to support the product's first human trials.
Chembio Diagnostics and LumiraDx entered into a collaborative agreement that will involve developing point-of-care diagnostic assays for infectious diseases that present serious health threats around the world. LumiraDx will finance diagnostic test projects by Chembio contingent on certain milestones being satisfied, and Chembio will sell reagents to LumiraDx and receive royalties from the sale of products the partnership develops.
Boston Scientific generated $2.38 billion in net sales during the first quarter ending March 31, up from $2.16 billion during the same period a year earlier -- an increase driven by greater demand for its heart valves, pacemakers and other products. The company anticipates a reimbursement win from French insurers in 2020 for its Acurate valves and is ramping up production.
David Castleman was tapped to serve as inaugural vice president of research and development at CoreLink. Castleman, who has over 25 years of experience in the orthopedic device space, previously worked at Smith & Nephew, Medtronic and Zimmer Biomet.
The Aixplorer Mach 30 ultrasound scanner was introduced by SuperSonic Imagine. The device, which comes with a range of probes, features SonicPad for providing intuitive exam function control and enabling more focus on clinical data shown on the screen than on scanner controls.
Hologic's ThinPrep integrated imager, which is designed for automated Pap test imaging, was granted premarket approval by the FDA. The imager is intended for facilitating the identification of abnormal cells, analyzing samples in approximately 90 seconds.
In a 7-2 vote, the Supreme Court ruled that the inter partes review system for patents is constitutional and will remain in place. Drugmakers say the process puts patents covering drug franchises at risk.